Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 2,209 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control I Clear all
Terminated Phase 1Phase 2 Interventional

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

NCT02228304
View directory record Official record
Conditions
Macular Degeneration
Interventions
NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
Drug
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

NCT04314544
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
TILD, matching placebo injections
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
45
States / cities
Dothan, Alabama • Gilbert, Arizona • Glendale, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

NCT00071409
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
INGAP-Peptide, placebo
Drug
Lead sponsor
Exsulin Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Irvine, California • San Diego, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 29, 2026, 10:07 PM EDT
Recruiting Not applicable Interventional

Home-Based Leg Dexterity Trainer for Management of Knee Osteoarthritis

NCT07397806
View directory record Official record
Conditions
Osteo Arthritis of the Knee
Interventions
Lex Dexterity Trainer, Wobble Board
Device
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
40 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Recruiting Phase 2 Interventional

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

NCT05595499
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Fisetin, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Alhambra, California • Beverly Hills, California • Burbank, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy (PRK)

NCT04281004
View directory record Official record
Conditions
Photorefractive Keratectomy
Interventions
Amniotic Fluid (AFED), Saline Solution
Biological · Other
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults

NCT00002204
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine
Biological
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 10:07 PM EDT
Terminated Phase 2 Interventional

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

NCT01340599
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, questionnaire administration, therapeutic conventional surgery, high performance liquid chromatography, mass spectrometry
Dietary Supplement · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 29, 2026, 10:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event

NCT01832714
View directory record Official record
Conditions
Concussion, Mild, Concussion, Intermediate, Concussion, Severe
Interventions
Not listed
Lead sponsor
Neurolign
Industry
Eligibility
19 Years to 45 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

NCT01452828
View directory record Official record
Conditions
Renal Impairment
Interventions
TR-701 FA single infusion, TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 29, 2026, 10:07 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

NCT06951698
View directory record Official record
Conditions
Bipolar-I Disorder With Mania or Mania With Mixed Features
Interventions
KarXT, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

NCT01656252
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703

NCT01982747
View directory record Official record
Conditions
Healthy
Interventions
MGN-Placebo, Placebo-MGN
Drug
Lead sponsor
Mologen AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers

NCT00532467
View directory record Official record
Conditions
Healthy
Interventions
SRX251
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

NCT03906006
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 29, 2026, 10:07 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

NCT03958877
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BIIB017 (peginterferon beta-1a), Interferon beta type 1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 18 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional

Healthy Caregivers-Healthy Children (HC2) Phase II

NCT02697565
View directory record Official record
Conditions
Pediatric Obesity, Obesity
Interventions
Healthy Caregivers- Healthy Children Toolkit, Safety Curriculum
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
2 Years to 5 Years
Enrollment
2,289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)

NCT05528263
View directory record Official record
Conditions
Acupuncture, Early-stage Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
Acupuncture, Nature scenery with a relaxation exercise
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Not applicable Interventional

SMART Project in Preventing Skin Cancer

NCT03177057
View directory record Official record
Conditions
Skin Carcinoma
Interventions
Compliance Monitoring, Health Telemonitoring, Questionnaire Administration
Behavioral · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 29, 2026, 10:07 PM EDT
Recruiting Not applicable Interventional

The Gender Inclusive Sexuality Talks Program

NCT07825571
View directory record Official record
Conditions
HIV/STI Incidence, Communication About Health Information
Interventions
The Gender Inclusive Sexuality Talks Program, GIST Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
12 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Terminated Not applicable Interventional

Control:Diabetes Pilot Study I

NCT04158921
View directory record Official record
Conditions
Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
Interventions
Control:Diabetes mobile app
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 29, 2026, 10:07 PM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Impact of Digital Behavioral Interventions to Address Insomnia and Depression in Breast Cancer Survivors Using an Adaptive Design

NCT07721064
View directory record Official record
Conditions
Insomnia, Depression
Interventions
Digital Insomnia Program, Digital Mental Health Program, Psychoeducation
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 29, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

NCT04583228
View directory record Official record
Conditions
COVID 19
Interventions
HLX71, Placebo
Drug · Other
Lead sponsor
Hengenix Biotech Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 29, 2026, 10:07 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

NCT01467700
View directory record Official record
Conditions
Acute Depressive Episode
Interventions
Ramelteon SL, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
141
States / cities
Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 29, 2026, 10:07 PM EDT